CN1883492B - 20(R)-人参皂苷Rg3药用组合物水溶液及制备方法 - Google Patents

20(R)-人参皂苷Rg3药用组合物水溶液及制备方法 Download PDF

Info

Publication number
CN1883492B
CN1883492B CN2006100466172A CN200610046617A CN1883492B CN 1883492 B CN1883492 B CN 1883492B CN 2006100466172 A CN2006100466172 A CN 2006100466172A CN 200610046617 A CN200610046617 A CN 200610046617A CN 1883492 B CN1883492 B CN 1883492B
Authority
CN
China
Prior art keywords
ginsenoside
water
solution
aqueous solution
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN2006100466172A
Other languages
English (en)
Chinese (zh)
Other versions
CN1883492A (zh
Inventor
富力
赫澜铭
刘红
鲁明明
鲁岐
Original Assignee
富力
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 富力 filed Critical 富力
Priority to CN2006100466172A priority Critical patent/CN1883492B/zh
Publication of CN1883492A publication Critical patent/CN1883492A/zh
Priority to CA2653085A priority patent/CA2653085C/en
Priority to KR1020087031196A priority patent/KR20090014300A/ko
Priority to ES07721208.2T priority patent/ES2477873T3/es
Priority to JP2009511321A priority patent/JP5525814B2/ja
Priority to EP07721208.2A priority patent/EP2025339B1/en
Priority to US12/301,996 priority patent/US8487090B2/en
Priority to PCT/CN2007/001635 priority patent/WO2007134534A1/zh
Priority to AU2007252183A priority patent/AU2007252183B2/en
Priority to RU2008150468/15A priority patent/RU2432164C2/ru
Priority to KR1020127011500A priority patent/KR101221680B1/ko
Application granted granted Critical
Publication of CN1883492B publication Critical patent/CN1883492B/zh
Priority to US13/941,106 priority patent/US9333215B2/en
Anticipated expiration legal-status Critical
Active legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
    • A61K36/258—Panax (ginseng)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Nanotechnology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Medical Informatics (AREA)
  • Immunology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Botany (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CN2006100466172A 2006-05-22 2006-05-22 20(R)-人参皂苷Rg3药用组合物水溶液及制备方法 Active CN1883492B (zh)

Priority Applications (12)

Application Number Priority Date Filing Date Title
CN2006100466172A CN1883492B (zh) 2006-05-22 2006-05-22 20(R)-人参皂苷Rg3药用组合物水溶液及制备方法
US12/301,996 US8487090B2 (en) 2006-05-22 2007-05-18 Water solution of 20(R)-ginsenoside Rg3 pharmaceutical composition and process thereof
AU2007252183A AU2007252183B2 (en) 2006-05-22 2007-05-18 Water solution of 20(R)-ginsenoside Rg3 pharmaceutical composition and process thereof
ES07721208.2T ES2477873T3 (es) 2006-05-22 2007-05-18 Disolución acuosa de composición farmacéutica de 20(R)-ginsenósido Rg3 y procedimiento de la misma
JP2009511321A JP5525814B2 (ja) 2006-05-22 2007-05-18 ２０（Ｒ）−人参サポニン（ジンセノサイド）Ｒｇ３薬用組成物水溶液の調製方法
EP07721208.2A EP2025339B1 (en) 2006-05-22 2007-05-18 WATER SOLUTION OF 20(R)-GINSENOSIDE Rg3 PHARMACEUTICAL COMPOSITION AND PROCESS THEREOF
CA2653085A CA2653085C (en) 2006-05-22 2007-05-18 Aqueous solution of 20(r)-ginsenoside rg3 pharmaceutical composition and process thereof
PCT/CN2007/001635 WO2007134534A1 (fr) 2006-05-22 2007-05-18 Solution aqueuse de composition pharmaceutique de 20(r)-ginsenoside rg3 et procédé correspondant
KR1020087031196A KR20090014300A (ko) 2006-05-22 2007-05-18 20 （Ｒ）­Ｇｉｎｓｅｎｏｓｉｄｅ Ｒｇ３ 약용조합물 수성솔루션과 준비방법
RU2008150468/15A RU2432164C2 (ru) 2006-05-22 2007-05-18 ВОДНЫЙ РАСТВОР ФАРМАЦЕВТИЧЕСКОЙ КОМПОЗИЦИИ 20(R)-ГИНСЕНОЗИДА Rg3 И СПОСОБ ЕГО ПРИГОТОВЛЕНИЯ
KR1020127011500A KR101221680B1 (ko) 2006-05-22 2007-05-18 20 （Ｒ）­Ｇｉｎｓｅｎｏｓｉｄｅ Ｒｇ３ 약용조합물 수성 솔루션과 준비방법
US13/941,106 US9333215B2 (en) 2006-05-22 2013-07-12 Aqueous solution of 20(R)-ginsenoside RG3 pharmaceutical composition and process thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2006100466172A CN1883492B (zh) 2006-05-22 2006-05-22 20(R)-人参皂苷Rg3药用组合物水溶液及制备方法

Publications (2)

Publication Number Publication Date
CN1883492A CN1883492A (zh) 2006-12-27
CN1883492B true CN1883492B (zh) 2010-07-28

Family

ID=37581875

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2006100466172A Active CN1883492B (zh) 2006-05-22 2006-05-22 20(R)-人参皂苷Rg3药用组合物水溶液及制备方法

Country Status (10)

Country Link
US (2) US8487090B2 (https=)
EP (1) EP2025339B1 (https=)
JP (1) JP5525814B2 (https=)
KR (2) KR20090014300A (https=)
CN (1) CN1883492B (https=)
AU (1) AU2007252183B2 (https=)
CA (1) CA2653085C (https=)
ES (1) ES2477873T3 (https=)
RU (1) RU2432164C2 (https=)
WO (1) WO2007134534A1 (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011512404A (ja) * 2008-02-19 2011-04-21 ユニジェン インク． 運動能力、疲労回復および抗酸化活性の改善のための、Ｐａｎａｘ（トチバニンジン属）の種の植物の葉の抽出物または処理されたＰａｎａｘ種植物葉抽出物または双方の混合物を含む組成物
CN101530389B (zh) * 2008-03-11 2012-02-15 沈阳市万嘉生物技术研究所 人参皂苷Rg3磷脂复合物及其制备方法
CN102091114B (zh) * 2009-12-15 2014-11-26 河北以岭医药研究院有限公司 一种中药冻干注射剂及其制备方法
KR100992800B1 (ko) * 2010-05-14 2010-11-08 주식회사 지씨에이치앤피 미량의 진세노사이드 성분이 증가된 신규한 가공인삼 또는 가공인삼추출물의 제조방법
CN103845280B (zh) * 2012-11-30 2017-04-12 富力 一种20(R)‑人参皂苷Rg3外用制剂、制法与用途
CN103845348B (zh) * 2012-11-30 2016-07-13 富力 20(R)-人参皂苷Rg3在制备痛经药物中的应用
KR101316095B1 (ko) * 2013-01-30 2013-10-11 경희대학교 산학협력단 진세노사이드 Ｒｂ１ 및 Ｒｇ３，Ｃｏｍｐｏｕｎｄ Ｋ，또는 인삼유래 사포닌 추출물을 유효성분으로 함유하는 신경병증성 통증 예방 및 치료용 조성물
KR102021463B1 (ko) * 2013-04-24 2019-09-16 (주)아모레퍼시픽 진세노사이드 Rg3를 함유하는 피부 외용제 조성물
KR101595426B1 (ko) 2013-08-30 2016-02-18 (주)녹십자웰빙 진세노사이드 성분이 증가된 가공인삼분말 또는 가공인삼추출물을 함유하는 암 관련 피로의 예방 및 치료용 조성물
CN104643058A (zh) * 2013-11-21 2015-05-27 富力 20(R)-人参皂苷Rg3在制备改善或/和治疗肝硬化疾病的药物中的应用
CN104644658A (zh) * 2013-11-22 2015-05-27 富力 人参皂苷Rg3在制备用于预防或/和治疗痴呆病症药物中的应用及药物
CN105012315A (zh) * 2014-04-24 2015-11-04 上海中医药大学 20(r)-原人参二醇的医药用途
CN105777838A (zh) * 2014-12-17 2016-07-20 富力 20(R)-人参皂苷Rg3衍生物、制备方法及其应用
CN105982906A (zh) * 2015-02-11 2016-10-05 富力 20(R)-人参皂苷Rg3在制备缓解或/和治疗类风湿病症的药物或保健品中的应用及药物
KR101772759B1 (ko) 2015-09-25 2017-08-30 순천향대학교 산학협력단 안정화된 무정형의 20(R)-진세노사이드 Rg3, 이의 제조방법 및 이를 함유하는 약제학적 제제
CN105878206A (zh) * 2016-03-31 2016-08-24 北京万全德众医药生物技术有限公司 一种人参皂苷Rg3的软胶囊及其制备方法
KR20180000379A (ko) * 2016-06-22 2018-01-03 재단법인 지능형 바이오 시스템 설계 및 합성 연구단 진세노사이드 f1을 유효성분으로 포함하는 면역증강용 조성물
CN108310106A (zh) * 2018-03-30 2018-07-24 吉林省恒实传食品科技发展有限公司 一种补肾填髓、健脑益智、辅助改善记忆的中药组合物及其应用
KR20200112012A (ko) * 2019-03-20 2020-10-05 순천대학교 산학협력단 (R)-진세노사이드 Rg3를 유효성분으로 포함하는 피부상처 치유 또는 피부재생 촉진용 조성물
CN111686104A (zh) * 2020-07-01 2020-09-22 香港浸会大学深圳研究院 小白菊内酯、木犀草素、金圣草素和人参皂苷Rg3的新用途
CN112245443A (zh) * 2020-08-25 2021-01-22 富力 人参皂苷Rg3与Rg5的组合物及其抗肿瘤等药用
CN116077442A (zh) * 2023-01-06 2023-05-09 吉林大学 一种含有人参皂苷Rg3的纳米颗粒及其制备方法和应用
KR102756809B1 (ko) * 2023-10-13 2025-01-22 표재성 난용성 진세노사이드의 수용해도를 높인 조성물, 이를 이용한 화장품조성물 및 건강기능식품

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1186015C (zh) 2001-01-18 2005-01-26 天津实验动物中心 用于冠心病心绞痛的中药复方口腔贴膜
CN1167734C (zh) * 2001-07-02 2004-09-22 董英杰 人参皂甙Rg3羟丙基-β-环糊精包合物及制剂和制备方法
CN1526405A (zh) * 2003-01-06 2004-09-08 山东绿叶天然药物研究开发有限公司 抗肿瘤的人参皂苷Rg3注射剂及其制备方法
CN1569012A (zh) * 2003-07-24 2005-01-26 山东绿叶天然药物研究开发有限公司 20(R)－人参皂苷－Rg3在制备治疗或预防高血压的药物中的应用
CN1569011A (zh) 2003-07-24 2005-01-26 山东绿叶天然药物研究开发有限公司 20（R）－人参皂苷－Rg3在制备治疗或预防心脑血管疾病的药物中的应用
WO2005034963A1 (en) * 2003-10-15 2005-04-21 Panagin Pharmaceuticals Inc. USE OF GINSENOSIDES Rh2 & Rg3, AND AGLYCON GINSENOSIDES FOR THE PREVENTION OF CANCER

Also Published As

Publication number Publication date
EP2025339A1 (en) 2009-02-18
RU2008150468A (ru) 2010-06-27
JP2009537572A (ja) 2009-10-29
AU2007252183B2 (en) 2013-07-11
KR20120054664A (ko) 2012-05-30
US9333215B2 (en) 2016-05-10
CA2653085C (en) 2016-01-19
US20130345156A1 (en) 2013-12-26
CN1883492A (zh) 2006-12-27
ES2477873T3 (es) 2014-07-18
KR101221680B1 (ko) 2013-01-11
KR20090014300A (ko) 2009-02-09
JP5525814B2 (ja) 2014-06-18
AU2007252183A1 (en) 2007-11-29
US20120149656A1 (en) 2012-06-14
US8487090B2 (en) 2013-07-16
WO2007134534A1 (fr) 2007-11-29
RU2432164C2 (ru) 2011-10-27
EP2025339A4 (en) 2013-01-16
CA2653085A1 (en) 2007-11-29
EP2025339B1 (en) 2014-04-16

Similar Documents

Publication Publication Date Title
CN1883492B (zh) 20(R)-人参皂苷Rg3药用组合物水溶液及制备方法
CN103319479B (zh) 大黄酸小檗碱离子对化合物、制备方法及应用
CN103319619B (zh) 粒毛盘菌胞外多糖磷酸化衍生物及其在制备抗肿瘤药物中的应用
CN114288278A (zh) 一种载药微藻、制备方法及其应用
CN101947234A (zh) 含有氨基葡萄糖制剂的制备方法及其应用
CN104707148A (zh) 一种用于抗肝癌的聚乙二醇改性甘草次酸和姜黄素复合物及其制备方法
CN101416959B (zh) 15-亚甲基取代穿心莲内酯衍生物在制备抗炎解热镇痛药物中的用途
JPH04230324A (ja) 水分散性ポリエン抗菌性複合体
US11491232B2 (en) Lactuloside compounds and preparation and use thereof
CN106631957A (zh) 一种靶向FAP‑alpha酶的抗肿瘤化合物及其制备方法与应用
CN102008494B (zh) 20(R)-人参皂苷Rg3药用水溶性中间体和冻干粉针剂及制备方法
US7863337B2 (en) Use of triacontanol in preparation of medicaments for treatment of cancers
CN109260217A (zh) 3`-脱氧次黄嘌呤核苷在制备用于多种疾病药品、食品或保健品中的应用
CN102579419B (zh) 绿原酸的抗癌用途
WO2006047931A1 (fr) Application du dipyridamole dans la fabrication de médicaments contre les tumeurs malignes
CN102526714B (zh) 治疗肿瘤的药物组合物及其制备方法
CN102423314A (zh) 一种治疗免疫性肝损伤或免疫性肝纤维化的药物
CN102920746B (zh) 一种虫草斑蝥组合物、肠溶制剂及其应用和制法
CN106806376A (zh) 对乙酰氨基酚和甘草酸或其盐或其衍生物的药物组合物
CN121041346A (zh) 一种中西结合抗肿瘤的法罗培南组合物及其制备方法
CN102240298B (zh) 一种抗肿瘤的药物组合物
CN104055777A (zh) 一种含有甲硫氨酸维b1的冻干药物组合物及制备方法
CN120241684A (zh) 一种促进糖尿病药物传递的组合物及其制备方法
CN102920702A (zh) 一种双氢青蒿斑蝥组合物、肠溶制剂及其应用和制法
CN109453195A (zh) 一种用于抑制肿瘤细胞的药物组合物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
EE01 Entry into force of recordation of patent licensing contract

Assignee: Jilin Yatai Pharmaceutical Co., Ltd.

Assignor: Fu Li

Contract record no.: 2011220000040

Denomination of invention: 20 (R) - ginsenoside Rg3 medical composition, aqueous solution and preparation method

Granted publication date: 20100728

License type: Exclusive License

Open date: 20061227

Record date: 20110902

EC01 Cancellation of recordation of patent licensing contract

Assignee: Jilin Yatai Pharmaceutical Co., Ltd.

Assignor: Fu Li

Contract record no.: 2011220000040

Date of cancellation: 20160919

LICC Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model